en · de · es · pt
methods-notes.peptides4800.com › Wiki › Tb-500 Identity And Molecular Background — Reference Sheet

Tb-500 Identity And Molecular Background — Reference Sheet

By Editorial Desk · published 2025-09-03 · last reviewed 2025-10-12 · Wiki

research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-10-12. Numbers and descriptions here follow the published literature rather than marketing material.

TB-500 Identity and Molecular Background

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

Research Framing and Evidence Base

Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.

Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.

Tb-500 at a glance

PropertyValueNotes
Molecular formulaC38H68N10O14Calculated for the acetylated heptapeptide
Molecular weight~889 DaMonoisotopic mass approximately 889.0 Da
Amino acid sequenceAc-LKKTETQN-terminal acetylated seven-residue peptide
AppearanceWhite to off-white powderTypically supplied as a lyophilized solid
Solubility classWater-solublePeptides of this size generally dissolve in aqueous media

Identity And Naming Background

Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.

Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.

Related pages on this site

TB-500 Identity and Naming Background

Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.

TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.

Storage and Analytical Verification

Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.

Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.

Identification and Molecular Background

Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.

Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.

TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.

Supporting material

== Bandyopadhyay-Mehler protein structure based scales == Most of the existing hydrophobicity scales are derived from the properties of amino acids in their free forms or as a part of a short peptide. Bandyopadhyay-Mehler hydrophobicity scale was based on partitioning of amino acids in the context of protein structure. Protein structure is a complex mosaic of various dielectric medium generated by arrangement of different amino acids. Hence, different parts of the protein structure most likely would behave as solvents with different dielectric values. For simplicity, each protein structure was considered as an immiscible mixture of two solvents, protein interior and protein exterior. The local environment around individual amino acid (termed as "micro-environment") was computed for both protein interior and protein exterior. The ratio gives the relative hydrophobicity scale for individual amino acids. Computation was trained on high resolution protein crystal structures. This quantitative descriptor for microenvironment was derived from the octanol-water partition coefficient, (known as Rekker's Fragmental Constants) widely used for pharmacophores. This scale well correlate with the existing methods, based on partitioning and free energy computations. Advantage of this scale is it is more realistic, as it is in the context of real protein structures.

The complement component C5 can be also activated by fluid phase C5 convertase. C5 is activated by CVFBb in the presence of complement component C6 and the C5b6 complex is formed. However, when C6 is added after C5 has been converted to C5b, the C5b6 complex fails to form. Therefore, the activation of C5 results in a transient binding site for C6. Hydrophobic sites are probably exposed upon C5 activation because C5b undergoes aggregation when C5 is converted to C5b in the absence of C6. Interactions between C5 and C6 or C5 and membranes are noncovalent. (In contrast, it is the labile thiol ester that permits covalent attachment between C3 and nucleophilic acceptors.) The proteolytic cleavage of C5 is the only known enzymatic event in assembly of the cytolytic membrane attack complex of complement. Once bound, C5 is exceptionally efficient in producing hemolysis, requiring less than seven specifically bound molecules per cell for the production of a hemolytic lesion. The extent of formation of the C5 intermediate complex is primarily dependent on the number of molecules of C4, C2 and C3 present on the cells employed for its generation. In these respects, the mode of action of C5 is completely analogous to that of the other components of complement. The C5 step differs, however, in other aspects. The binding of C5 is influenced by C6 and C7, components which are thought to act subsequent to it in the complement sequence. In addition, the hemolytic activity of the isolated C5 intermediate complex is exceedingly labile, having an average half-life at 30 °C of only 9 min.

=== Opioid liability === Systemic agmatine can potentiate opioid analgesia, and prevent tolerance to chronic morphine in laboratory rodents. Since then, cumulative evidence amply shows that agmatine inhibits opioid dependence and relapse in several animal species.

== Medical uses == EDE, a long-acting estrogen, was used in combination with EB, a short-acting estrogen, and TEBH, a long-acting androgen/anabolic steroid, in menopausal hormone therapy in perimenopausal, postmenopausal, hypogonadal, and oophorectomized women, as well as for suppression of lactation in postpartum women.

== Pathophysiology == Hemoglobin is a protein containing iron that facilitates the transportation of oxygen in red blood cells. Hemoglobin in the blood carries oxygen from the lungs to the other tissues of the body, where it releases the oxygen to enable metabolism. A healthy level of hemoglobin for men is between 13.2 and 16.6 grams per deciliter, and in women between 11.6 and 15 g/dl. Normal adult hemoglobin (HbA) is composed of four protein chains, two α and two β-globin chains arranged into a heterotetramer. In thalassemia, patients have defects in the noncoding region of either the α or β-globin genes, causing ineffective production of normal alpha- or beta-globin chains, which can lead to ineffective erythropoiesis, premature red blood cell destruction, and anemia. The thalassemias are classified according to which chain of the hemoglobin molecule is affected. In α-thalassemias, production of the α-globin chain is affected, while in β-thalassemia, production of the β-globin chain is affected.

Sources: en.wikipedia.org

Notes from published material

=== Late onset form === The Late-onset (LOPD) form differs from the infantile-onset principally in the relative lack of cardiac involvement. The onset has a slower progression and can present at any decade of life. Cardiac involvement may occur but is milder than in the infantile form. Skeletal involvement is more prominent with a predilection for the lower limbs. Late-onset features include impaired cough, recurrent chest infections, hypotonia, progressive muscle weakness, delayed motor milestones, difficulty swallowing or chewing, and reduced vital capacity. Variability in the age of onset, severity, and symptoms, between those as genetically similar as identical twins, indicates that there may be epigenetic - or secondary factors - influencing disease presentation. Prognosis depends on the age of onset of symptoms with a better prognosis being associated with later onset disease.

During the British Raj, there were multiple American missionaries sent to India, including the well known Scudder family, Ralph T. Templin, James Mills Thoburn, Mary W. Bacheler, James Mudge, J. Waskom Pickett, Edward Winter Clark, Miles Bronson, Samuel H. Kellogg, John Nelson Hyde, Nancie Monelle, Lucy Whitehead McGill Waterbury Peabody, Crawford R. Thoburn, Elwood Morris Wherry, Murray Thurston Titus, Titanic victim Annie Funk, Frederick Bohn Fisher, British Raj born & World War II victim Robert M. Hanson, British Raj born Victor Clough Rambo, Hervey De Witt Griswold, British Raj born Robert Ernest Hume, British Raj born John Lawrence Goheen, British Raj born John William Theodore Youngs, Beatrice Marian Smyth, Anna Sarah Kugler, William H. Wiser, Julia Jacobs Harpster, Charlotte C. Wyckoff, Isabella Thoburn, and American expatriate turned Indian freedom fighter Satyananda Stokes. The Scudder family was renowned for its multigenerational missionary work in India, particularly in the fields of medicine, education, and Christian evangelism. Led by Dr. John Scudder Sr., who arrived in South Asia in 1819 as one of the first medical missionaries sent by the American Board of Commissioners for Foreign Missions (ABCFM), the family established hospitals and dispensaries across the region. Dr. John Scudder Jr. continued this legacy, founding the Arcot Mission in Vellore, Tamil Nadu, and later the Ceylon Mission in Sri Lanka. Notably, Dr. Ida Scudder, granddaughter of Dr.

The endoneurium (also called endoneurial channel, endoneurial sheath, endoneurial tube, or Henle's sheath) is a layer of delicate connective tissue around the myelin sheath of each myelinated nerve fiber in the peripheral nervous system. Its component cells are called endoneurial cells. The endoneuria with their enclosed nerve fibers are bundled into groups called nerve fascicles, each fascicle within its own protective sheath called a perineurium. If sufficiently large, nerves containing multiple fascicles, each with its blood supply and fatty tissue, may be bundled within yet another sheath, the epineurium. The endoneurium contains a liquid known as endoneurial fluid, which contains little protein. In the peripheral nervous system the endoneurial fluid is notionally equivalent to cerebrospinal fluid in the central nervous system. Peripheral nerve injuries commonly release increased amounts of endoneurial fluid into surrounding tissues; these can be detected by magnetic resonance neurography, thereby assisting in locating injuries to peripheral nerves. The endoneurium runs longitudinally along the nerve fiber, but with discontinuities where septa pass inward from the innermost layer of the perineurium. It contains fine bundles of fibrous connective tissue, primarily collagen, embedded in a matrix of ground substance. This structure serves to support capillary blood vessels, arranged so as to form a network of elongated meshes.

Atractyloside is found in numerous plant species in the daisy family e.g. Atractylis gummifera, Callilepis laureola, Xanthium strumarium, Iphiona alsoeri, Pascalia glauca, Wedelia glauca, and Iphiona aucheri among others. It is also found in very low concentrations in Coffea arabica. The widespread regions across all of these plants' native areas of growth results in ATR's easy availability worldwide. However the ATR concentration found in plants is dependent upon the species, season, and origin. For example, the ATR content measured in dried Atractlyis gummifera between Sardinia, Italy and Sicily, Italy revealed a higher content in the Sicilian region by nearly a factor of five, and a higher content in colder months across both regions. Additionally, the preparation of plants with atractyloside in some traditional medicines affects the atractyloside content. The preparation technique, such as decoction or infusion, extracts the desired chemical compound, after which the contents could be diluted or concentrated.

Sources: en.wikipedia.org

Background from the literature

Theranos claimed to have data verifying the accuracy and reliability of its tests that would be published. In February 2016, Theranos announced that it would permit the Cleveland Clinic to complete a validation study of its technology. In March 2016, a study authored by 13 scientists appeared in the Journal of Clinical Investigation, where it was stated that the company's blood test results were flagged "outside their normal range 1.6× more often than other testing services", that 68 percent of lab measurements evaluated "showed significant interservice variability", and that "lipid panel test results between Theranos and other clinical services" were "nonequivalent". In August 2016, the company introduced a new robotic capillary blood testing unit named "miniLab" at the 2016 annual meeting of the American Association for Clinical Chemistry, but did not present any data supporting the claimed abilities of the device. The miniLab was allegedly capable of carrying out a range of tests from a small amount of blood. After Theranos failed to address concerns that it exaggerated the capabilities of the miniLab, Walgreens withdrew from their partnership. It was later revealed that Theranos had voided two years of test results showing inaccuracies with the Edison technology.

== Medical uses == The most common indication for butorphanol is management of migraine using the intranasal spray formulation. It may also be used parenterally for management of moderate-to-severe pain, as a supplement for balanced general anesthesia, and management of pain during labor. Butorphanol is also quite effective at reducing post-operative shivering (owing to its kappa agonist activity). Butorphanol is more effective in reducing pain in women than in men.

The earliest cultures have used sugar as a preservative, and it was commonplace to store fruit in honey. "Sugar tends to draw water from the microbes (plasmolysis). This process leaves the microbial cells dehydrated, thus killing them. In this way, the food will remain safe from microbial spoilage." In northern climates without sufficient sun to dry foods, preserves are made by heating the fruit with sugar. Sugar is used to preserve fruits, either in an antimicrobial syrup with fruit such as apples, pears, peaches, apricots, and plums, or in crystallized form where the preserved material is cooked in sugar to the point of crystallization and the resultant product is then stored dry. The latter method is used for the skins of citrus fruit (candied peel), angelica, and ginger.

European Network for the Investigation of Gender Incongruence (ENIGI) Healthcare and the LGBTQ community Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People Study of Transition, Outcomes, and Gender (STRONG) Transgender § Healthcare Transgender clinic Transgender health care misinformation

In 2013, Wolk was offered the position of Director of Clinical Microbiology in the Geisinger Health System, where she was honored by the American Society for Microbiology for her efforts to improve patient care and medical outcomes using microbiology. Wolk demonstrated that mass spectrometry could be used to differentiate biomarkers of anti-microbial resistance as well as in the diagnosis of bacteria and yeasts.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500?

TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.

Is TB-500 identical to thymosin beta-4?

No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.

How does TB-500 appear in the literature?

It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.

What mechanism is most often proposed?

The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.

Network